Pegylated Liposomal Doxorubicin

Phase 3Small molecule

Merck & Co.

Pegylated Liposomal Doxorubicin is one of 307 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

306

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

HistiocytosisActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Cervical CarcinomaActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Breast CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Bladder CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Ovarian NeoplasmsNot yet recruiting

LymphomaPhase 3

Active, not recruiting

HistiocytosisPhase 3

Active, not recruiting

Triple-Negative Breast CancerPhase 2

Active, not recruiting

Cervical CarcinomaPhase 3

Active, not recruiting

Fallopian Tube CancerPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 2/Phase 3

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Ovarian NeoplasmsPhase 3

Not yet recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

17 2

Halaven

Eisai

Preclinical

38 3

Tykerb

GSK

Preclinical

80 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

MS Contin

Merck & Co.

Preclinical

2 6

Lexiscan

Astellas

Preclinical

1 7

Acupan

YYonsei University

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Ovarian Cancer

NCT04274426

Phase 2Recruiting

Ovarian Cancer

NCT06014528

Q1 2027

Phase 1Recruiting

Ovarian Cancer

NCT04516447

Q3 2027

Phase 1/2Recruiting

Ovarian Cancer

NCT05271318

Q1 2028

Phase 3Recruiting

Breast Cancer

NCT05159193

Clinical

Trials by Indication[1]

Ovarian Cancer36 trials

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01121406·110 enrolled

Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin

Completed·GGrupo Español de Investigación en Cáncer de Ovario·Phase 2·NCT03161132·32 enrolled

Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer

Unknown status·FFudan University··NCT05976932·20 enrolled

Show 33 more trials

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03467178·119 enrolled

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer

Completed·NNational Cheng-Kung University Hospital·Phase 1/2·NCT03480750·18 enrolled

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Terminated·MMural Oncology, Inc·Phase 3·NCT05092360·456 enrolled

A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer

Terminated· Astellas logo

Astellas·Phase 1·NCT01016054·4 enrolled

Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type

Completed·VVejle Hospital·Phase 2·NCT00861120·33 enrolled

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

Completed·AAGC Biologics S.p.A.·Phase 2·NCT03804866·14 enrolled

A Study of ZN-c3 in Patients With Ovarian Cancer

Recruiting·KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.·Phase 1·NCT04516447·140 enrolled

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Withdrawn· Takeda logo

Takeda·Phase 2·NCT00610792·91 enrolled

A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00780039·58 enrolled

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT01113957·168 enrolled

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting·AAGO Research GmbH·Phase 2·NCT04274426·136 enrolled

Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT03596281·47 enrolled

Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)

Completed·EEndocyte·Phase 2·NCT00722592·162 enrolled

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Terminated· Novartis logo

Novartis·Phase 3·NCT04729387·358 enrolled

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Terminated·EEndocyte·Phase 3·NCT01170650·441 enrolled

Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer

Unknown status·WWiSP Wissenschaftlicher Service Pharma GmbH·Phase 2·NCT01388621·140 enrolled

Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients

Completed·PPharmaMar·Phase 3·NCT02421588·442 enrolled

Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

Completed·GGrupo Español de Investigación en Cáncer de Ovario·Phase 3·NCT03598270·417 enrolled

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Terminated· Pfizer logo

Pfizer·Phase 1/2·NCT05261490·10 enrolled

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT07218809·1,100 enrolled

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Completed·AAravive, Inc.·Phase 1·NCT03639246·53 enrolled

Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer

Completed·YYonsei University··NCT03367182·50 enrolled

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse

Completed·AARCAGY/ GINECO GROUP·Phase 3·NCT00189553·976 enrolled

Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT01802749·406 enrolled

Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer

Unknown status·WWomen's Hospital School Of Medicine Zhejiang University·Phase 4·NCT03794778·396 enrolled

Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Terminated· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 1·NCT01279291·22 enrolled

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Recruiting·TTILT Biotherapeutics Ltd.·Phase 1/2·NCT05271318·29 enrolled

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT03335241·140 enrolled

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Terminated·SSutro Biopharma, Inc.·Phase 2/3·NCT05870748·600 enrolled

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 2·NCT06014528·168 enrolled

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting·VVerastem, Inc.·Phase 3·NCT06072781·270 enrolled

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Completed·LLudwig Institute for Cancer Research·Phase 1/2·NCT02431559·53 enrolled

Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer

Completed·AAGC Biologics S.p.A.·Phase 2·NCT01358071·119 enrolled

Breast Cancer17 trials

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients

Unknown status·ZZhejiang University·Phase 4·NCT03123770·384 enrolled

Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)

Terminated· Merck & Co. logo

Merck & Co.·Phase 4·NCT00779285·1 enrolled

Phase II Study in Patients With Operable Breast Cancer

Unknown status·AAptium Oncology Research Network·Phase 2·NCT00518583·30 enrolled

Show 14 more trials

Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

Completed·UUS Oncology Research·Phase 2·NCT00303108·136 enrolled

Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients

Completed·SSpanish Breast Cancer Research Group·Phase 4·NCT00128778·288 enrolled

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT05159193·372 enrolled

The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00266799·210 enrolled

Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00431795·100 enrolled

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00687440·27 enrolled

Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

Unknown status·PPeking Union Medical College·Phase 1/2·NCT03994107·40 enrolled

Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00524810·67 enrolled

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Unknown status·SShanghai Pudong Hospital·N/A·NCT05656079·204 enrolled

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

Terminated· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00082095·62 enrolled

A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.··NCT00736333·167 enrolled

Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer

Completed·OOslo University Hospital·Phase 2·NCT03409198·82 enrolled

Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03933319·30 enrolled

Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer

Completed·HHerlev Hospital·Phase 2·NCT01206881·45 enrolled

Fallopian Tube Cancer5 trials

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

Completed·IImmunoGen, Inc.·Phase 3·NCT02631876·366 enrolled

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Completed·IImmunoGen, Inc.·Phase 1/2·NCT02606305·264 enrolled

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Completed· AbbVie logo

AbbVie·Phase 3·NCT04209855·453 enrolled

Show 2 more trials

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT05613088·106 enrolled

Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients

Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 3·NCT02903004·242 enrolled

Multiple Myeloma4 trials

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Withdrawn·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01492881

Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00617591·57 enrolled

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Unknown status·OOncotherapeutics·Phase 1/2·NCT01541332·70 enrolled

Show 1 more trial

Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·WWashington University School of Medicine·Phase 1/2·NCT01246063·40 enrolled

Ovarian Neoplasms3 trials

A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer

Recruiting· GSK logo

GSK·Phase 3·NCT07286266·450 enrolled

FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT07213804·1,630 enrolled

A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-Sensitive Ovarian Cancer

Not yet recruiting· GSK logo

GSK·Phase 3·NCT07684612·690 enrolled

21 more indications

Soft Tissue Sarcoma2 trials

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma

Recruiting·FFudan University·Phase 1/2·NCT05774275·52 enrolled

Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma

Unknown status·YYong Chen·Phase 2·NCT04765228·45 enrolled

Lymphoma2 trials

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Unknown status·PPeking University·Phase 3·NCT03952572·244 enrolled

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

Unknown status·WWenqi Jiang·Phase 3·NCT02428751·216 enrolled

Triple-Negative Breast Cancer2 trials

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT03719326·35 enrolled

Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer

Completed·OOslo University Hospital·Phase 2·NCT03164993·68 enrolled

Clear Cell Carcinoma2 trials

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

Unknown status·NNHS Greater Glasgow and Clyde·Phase 2·NCT02866370·120 enrolled

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Recruiting·YYonsei University·Phase 2·NCT06023862·198 enrolled

Primary Peritoneal Cancer2 trials

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01666444·297 enrolled

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Unknown status·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 3·NCT04679064·427 enrolled

Liposomal Doxorubicin2 trials

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Completed· Bayer logo

Bayer·Phase 1·NCT02751918·65 enrolled

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

Not yet recruiting·AAIDS Malignancy Consortium·Phase 3·NCT05411237·130 enrolled

Chemotherapy2 trials

Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy

Terminated·UUniversity of Arizona·Phase 2·NCT01990352·24 enrolled

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Unknown status·—·Phase 2·NCT04877275·50 enrolled

Platinum-resistant Ovarian Cancer2 trials

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

Not yet recruiting· Genmab logo

Genmab·Phase 3·NCT07604766·82 enrolled

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer

Active, not recruiting· Genmab logo

Genmab·Phase 3·NCT06619236·530 enrolled

Cervical Carcinoma1 trial

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Unknown status·AAdvenchen Laboratories, LLC·Phase 3·NCT02584478·294 enrolled

Neoadjuvant Chemotherapy1 trial

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

Unknown status·JJilin University·Phase 2·NCT02953184·160 enrolled

Histiocytosis1 trial

Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.

Unknown status·—·Phase 3·NCT04077905·160 enrolled

Bladder Cancer1 trial

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Unknown status·TTianjin Medical University Second Hospital·Phase 2·NCT04101812·60 enrolled

Advanced Solid Malignancies1 trial

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Terminated·AAtreca, Inc.·Phase 1·NCT04244552·87 enrolled

Peritoneal Cancer1 trial

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

Completed·—·Phase 2·NCT02865811·26 enrolled

Metastatic Soft-tissue Sarcoma1 trial

Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma

Withdrawn·PPeking University People's Hospital·Phase 2/3·NCT03342300

Solid Malignancies1 trial

Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies

Completed·WWashington University School of Medicine·Phase 1·NCT00703170·28 enrolled

Solid Tumors1 trial

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Completed· Sanofi logo

Sanofi·Phase 1·NCT01455532·59 enrolled

Bevacizumab1 trial

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

Unknown status·FFudan University·Phase 2·NCT05386524·41 enrolled

Ovarian Cancer Recurrent1 trial

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06843447·460 enrolled

Advanced Soft-tissue Sarcoma1 trial

Maintenance Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

Recruiting·NNational Health Research Institutes, Taiwan·Phase 2·NCT06981637·81 enrolled

Unspecified1 trial

Metronomic PLD in Patients With Primary Endocrine Resistant ABC

Unknown status·FFudan University·Phase 2·NCT03071926·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 94 trial records for Pegylated Liposomal Doxorubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegylated Liposomal Doxorubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegylated Liposomal Doxorubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Pegylated Liposomal Doxorubicin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q1 2028

Trials by Indication[1]

Ovarian Cancer36 trials

Breast Cancer17 trials

Fallopian Tube Cancer5 trials

Multiple Myeloma4 trials

Ovarian Neoplasms3 trials

Soft Tissue Sarcoma2 trials

Lymphoma2 trials

Triple-Negative Breast Cancer2 trials

Clear Cell Carcinoma2 trials

Primary Peritoneal Cancer2 trials

Liposomal Doxorubicin2 trials

Chemotherapy2 trials

Platinum-resistant Ovarian Cancer2 trials

Cervical Carcinoma1 trial

Neoadjuvant Chemotherapy1 trial

Histiocytosis1 trial

Bladder Cancer1 trial

Advanced Solid Malignancies1 trial

Peritoneal Cancer1 trial

Metastatic Soft-tissue Sarcoma1 trial

Solid Malignancies1 trial

Solid Tumors1 trial

Bevacizumab1 trial

Ovarian Cancer Recurrent1 trial

Advanced Soft-tissue Sarcoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News